- Home
- MAMA vs PGEN Comparison
MAMA vs PGEN Comparison
Compare MAMA & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAMA
- PGEN
- Stock Information
- Founded
- MAMA 2010
- PGEN 1998
- Country
- MAMA United States
- PGEN United States
- Employees
- MAMA N/A
- PGEN N/A
- Industry
- MAMA Specialty Foods
- PGEN Biotechnology: Pharmaceutical Preparations
- Sector
- MAMA Consumer Staples
- PGEN Health Care
- Exchange
- MAMA Nasdaq
- PGEN Nasdaq
- Market Cap
- MAMA 290.7M
- PGEN 292.6M
- IPO Year
- MAMA N/A
- PGEN N/A
- Fundamental
- Price
- MAMA $9.70
- PGEN $0.79
- Analyst Decision
- MAMA Strong Buy
- PGEN Buy
- Analyst Count
- MAMA 4
- PGEN 5
- Target Price
- MAMA $10.00
- PGEN $7.00
- AVG Volume (30 Days)
- MAMA 256.5K
- PGEN 943.5K
- Earning Date
- MAMA 12-10-2024
- PGEN 11-14-2024
- Dividend Yield
- MAMA N/A
- PGEN N/A
- EPS Growth
- MAMA N/A
- PGEN N/A
- EPS
- MAMA 0.13
- PGEN N/A
- Revenue
- MAMA $113,593,000.00
- PGEN $3,963,000.00
- Revenue This Year
- MAMA $18.91
- PGEN N/A
- Revenue Next Year
- MAMA $12.69
- PGEN $426.76
- P/E Ratio
- MAMA $74.18
- PGEN N/A
- Revenue Growth
- MAMA 17.81
- PGEN N/A
- 52 Week Low
- MAMA $3.46
- PGEN $0.76
- 52 Week High
- MAMA $9.97
- PGEN $1.93
- Technical
- Relative Strength Index (RSI)
- MAMA 69.32
- PGEN 38.43
- Support Level
- MAMA $7.65
- PGEN $0.76
- Resistance Level
- MAMA $9.98
- PGEN $0.97
- Average True Range (ATR)
- MAMA 0.41
- PGEN 0.07
- MACD
- MAMA 0.08
- PGEN -0.01
- Stochastic Oscillator
- MAMA 87.55
- PGEN 4.24
About MAMA Mama's Creations Inc.
Mama`s Creations Inc is a marketer and manufacturer of fresh deli-prepared foods, found in over 8,400 grocery, mass, club, and convenience stores nationally. The company's broad product portfolio, born from a rich history in Italian foods, now consists of a variety of high-quality, fresh, clean, and easy-to-prepare foods to address the needs of both consumers and retailers.
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.